[Pharmacokinetic and clinical studies of imipenem/cilastatin sodium in the pediatric field]. 1986

T Motohiro, and T Koga, and Y Shimada, and S Tomita, and T Fujimoto, and T Nishiyama, and K Tominaga, and F Yamashita, and K Suzuki, and O Toyoda

Pharmacokinetic and clinical studies of imipenem/cilastatin sodium (MK-0787/MK-0791), a newly developed combined antibiotic in a 1:1 ratio, were performed in the field of pediatrics. The MK-0787/MK-0791 was administered to 15 children. Ten and 20 mg/kg doses of MK-0787 were administered by a intravenous drip infusion for 30 minutes to 3 children each. In the remaining 9 cases, MK-0787 doses of 10, 20 and 30 mg/kg were administered to 3 children each by a 1 hour intravenous drip infusion. Levels of MK-0787 and MK-0791 in plasma, urine and urinary recovery rate of the drugs were also determined. In addition, MK-0787/MK-0791 was administered to a total of 29 children; 2 children with bronchitis, 16 with pneumonia, 4 with UTI, 2 with purulent lymphadenitis and 1 child each with tonsillitis, septicemia suspected disease, peritonitis, staphylococcal scalded skin syndrome and osteomyelitis/bacteremia. The average single dose was 15.3 mg/kg of MK-0787 and administrations were performed by 20-60 minutes intravenous drip infusion 3-4 times daily for an average period of 6 days. The clinical and bacteriological effects of this drug were evaluated in these cases and adverse reactions and unusual laboratory findings were also studied in a total of 33 cases including 4 other drop-out cases. Results of these studies were summarized as follows. In 6 children, 3 each who were given doses of 10 or 20 mg/kg, the mean peak plasma concentrations of the drugs were found at the end of the 30 minutes-infusion with values of 35.20 and 74.90 micrograms/ml for MK-0787 and 44.85 and 93.32 micrograms/ml for MK-0791 after the dose of 10 and 20 mg/kg, respectively. The peak plasma levels of MK-0791 were approximately 1.3 times higher than those of MK-0787 and higher peak levels were observed in the groups with larger doses of either drugs. In the 10 mg/kg group, the mean half-lives of MK-0787 and MK-0791 were 0.97 and 0.71 hour, respectively and those values were 0.89 and 0.63 hour, respectively in the 20 mg/kg group. In both group, MK-0787 tended to have longer half-lives than MK-0791. In 9 children, 3 each who were administered doses of 10, 20 and 30 mg/kg by a 1 hour intravenous drip infusion had the highest plasma levels for both MK-0787 and MK-0791 at the end of the infusion.(ABSTRACT TRUNCATED AT 400 WORDS)

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003521 Cyclopropanes Three-carbon cycloparaffin cyclopropane (the structural formula (CH2)3) and its derivatives.
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

T Motohiro, and T Koga, and Y Shimada, and S Tomita, and T Fujimoto, and T Nishiyama, and K Tominaga, and F Yamashita, and K Suzuki, and O Toyoda
July 1986, The Japanese journal of antibiotics,
T Motohiro, and T Koga, and Y Shimada, and S Tomita, and T Fujimoto, and T Nishiyama, and K Tominaga, and F Yamashita, and K Suzuki, and O Toyoda
July 1986, The Japanese journal of antibiotics,
T Motohiro, and T Koga, and Y Shimada, and S Tomita, and T Fujimoto, and T Nishiyama, and K Tominaga, and F Yamashita, and K Suzuki, and O Toyoda
July 1986, The Japanese journal of antibiotics,
T Motohiro, and T Koga, and Y Shimada, and S Tomita, and T Fujimoto, and T Nishiyama, and K Tominaga, and F Yamashita, and K Suzuki, and O Toyoda
July 1986, The Japanese journal of antibiotics,
T Motohiro, and T Koga, and Y Shimada, and S Tomita, and T Fujimoto, and T Nishiyama, and K Tominaga, and F Yamashita, and K Suzuki, and O Toyoda
July 1986, The Japanese journal of antibiotics,
T Motohiro, and T Koga, and Y Shimada, and S Tomita, and T Fujimoto, and T Nishiyama, and K Tominaga, and F Yamashita, and K Suzuki, and O Toyoda
June 1986, The Japanese journal of antibiotics,
T Motohiro, and T Koga, and Y Shimada, and S Tomita, and T Fujimoto, and T Nishiyama, and K Tominaga, and F Yamashita, and K Suzuki, and O Toyoda
July 1986, The Japanese journal of antibiotics,
T Motohiro, and T Koga, and Y Shimada, and S Tomita, and T Fujimoto, and T Nishiyama, and K Tominaga, and F Yamashita, and K Suzuki, and O Toyoda
November 1988, The Japanese journal of antibiotics,
T Motohiro, and T Koga, and Y Shimada, and S Tomita, and T Fujimoto, and T Nishiyama, and K Tominaga, and F Yamashita, and K Suzuki, and O Toyoda
November 1988, The Japanese journal of antibiotics,
T Motohiro, and T Koga, and Y Shimada, and S Tomita, and T Fujimoto, and T Nishiyama, and K Tominaga, and F Yamashita, and K Suzuki, and O Toyoda
May 1989, The Japanese journal of antibiotics,
Copied contents to your clipboard!